Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-Lung04: Rilvegostomig vs Pembrolizumab in 1L PD-L1-high mNSCLC
NCT06868277Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Primary completion
- Jan 2030
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial of rilvegostomig in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Overall Survival at 5 years and Progression-Free Survival at 5 years. Started Apr 2025; status: recruiting.
02
Drugs
rilvegostomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06868277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06868277.